» Articles » PMID: 38694765

Unrestricted Molecular Motions Enable Mild Photothermy for Recurrence-resistant FLASH Antitumor Radiotherapy

Abstract

Ultrahigh dose-rate (FLASH) radiotherapy is an emerging technology with excellent therapeutic effects and low biological toxicity. However, tumor recurrence largely impede the effectiveness of FLASH therapy. Overcoming tumor recurrence is crucial for practical FLASH applications. Here, we prepared an agarose-based thermosensitive hydrogel containing a mild photothermal agent (TPE-BBT) and a glutaminase inhibitor (CB-839). Within nanoparticles, TPE-BBT exhibits aggregation-induced emission peaked at 900 nm, while the unrestricted molecular motions endow TPE-BBT with a mild photothermy generation ability. The balanced photothermal effect and photoluminescence are ideal for phototheranostics. Upon 660-nm laser irradiation, the temperature-rising effect softens and hydrolyzes the hydrogel to release TPE-BBT and CB-839 into the tumor site for concurrent mild photothermal therapy and chemotherapy, jointly inhibiting homologous recombination repair of DNA. The enhanced FLASH radiotherapy efficiently kills the tumor tissue without recurrence and obvious systematic toxicity. This work deciphers the unrestricted molecular motions in bright organic fluorophores as a source of photothermy, and provides novel recurrence-resistant radiotherapy without adverse side effects.

Citing Articles

FLASH radiotherapy: mechanisms, nanotherapeutic strategy and future development.

Wang Y, Wang H, Hu J, Chai J, Luan J, Li J Nanoscale Adv. 2025; 7(3):711-721.

PMID: 39781242 PMC: 11705069. DOI: 10.1039/d4na00753k.


Hydrogel local drug delivery systems for postsurgical management of tumors: and perspectives.

Zhong Z, Gan L, Feng Z, Wang W, Pan X, Wu C Mater Today Bio. 2024; 29:101308.

PMID: 39525397 PMC: 11550774. DOI: 10.1016/j.mtbio.2024.101308.

References
1.
Zhao Y, Feng X, Chen Y, Selfridge J, Gorityala S, Du Z . 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against -Mutant Colorectal Cancers. Cancer Res. 2020; 80(21):4815-4827. PMC: 7642187. DOI: 10.1158/0008-5472.CAN-20-0600. View

2.
Goel N, Foxall M, Scalise C, Wall J, Arend R . Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance. Mol Cancer Ther. 2021; 20(9):1542-1549. PMC: 9066363. DOI: 10.1158/1535-7163.MCT-20-0992. View

3.
Galluzzi L, Aryankalayil M, Coleman C, Formenti S . Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023; 20(8):543-557. DOI: 10.1038/s41571-023-00782-x. View

4.
Alden R, Kamran M, Bashjawish B, Simone B . Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. Front Oncol. 2022; 12:1070514. PMC: 9712788. DOI: 10.3389/fonc.2022.1070514. View

5.
de Mey S, Dufait I, De Ridder M . Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. Front Oncol. 2021; 11:761901. PMC: 8579106. DOI: 10.3389/fonc.2021.761901. View